Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7240406 | 0.93 | ALOX5 (0.43) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7232083 | 0.80 | ALDH1A1 (0.42) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7241464 | 0.73 | CYP11B1 (0.42) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7233460 | 0.72 | SMN1; SMN2 (0.52) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7407222 | 0.71 | KDM4E (0.40) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7379148 | 0.71 | PSMD14 (0.40) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7233487 | 0.71 | EGFR (0.48) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7232639 | 0.71 | EGFR (0.37) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7231035 | 0.71 | CYP11B1 (0.40) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7230558 | 0.71 | PSMD14 (0.37) | ALDH1A1POLBKDM4ESMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552037-B2 | An imidazo(1,2-a)Pyridine compound useful for altering the signal-transducing activity of gamma-aminobuytric acid receptor | NEUROGEN CORPORATION | 2003-04-22 | — | — | US | claimed |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | claimed |
| US-6552037-B2 | An imidazo(1,2-a)Pyridine compound useful for altering the signal-transducing activity of gamma-aminobuytric acid receptor | NEUROGEN CORPORATION | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | ALDH1A1 403/4885POLB 2667/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.